Cargando…
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
SLC7A11/xCT is an antiporter that mediates the uptake of extracellular cystine in exchange for glutamate. Cystine is reduced to cysteine, which is a rate-limiting precursor in glutathione synthesis; a process that protects cells from oxidative stress and is, therefore, critical to cell growth, proli...
Autores principales: | Jyotsana, Nidhi, Ta, Kenny T., DelGiorno, Kathleen E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904967/ https://www.ncbi.nlm.nih.gov/pubmed/35280777 http://dx.doi.org/10.3389/fonc.2022.858462 |
Ejemplares similares
-
The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
por: Shin, Chun-Shik, et al.
Publicado: (2017) -
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
por: Lim, Jonathan K. M., et al.
Publicado: (2019) -
Implication of the glutamate–cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis
por: Fournier, M., et al.
Publicado: (2017) -
Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
por: Meyer, Anne R., et al.
Publicado: (2019) -
Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
por: Arensman, Michael D., et al.
Publicado: (2019)